Leerink Partnrs Has Bearish Estimate for Vericel Q4 Earnings

Vericel Corporation (NASDAQ:VCEL) – Analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for shares of Vericel in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now forecasts that the biotechnology company will earn $0.44 per share for the quarter, down from their prior estimate of $0.45. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel’s FY2026 earnings at $0.68 EPS, FY2027 earnings at $1.19 EPS, FY2028 earnings at $1.83 EPS and FY2029 earnings at $2.42 EPS.

A number of other research firms have also recently commented on VCEL. Truist Financial cut their price target on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a research note on Wednesday. BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Canaccord Genuity Group cut their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Vericel in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and an average target price of $58.40.

Vericel Trading Down 3.0%

Vericel stock opened at $33.59 on Wednesday. The firm’s 50 day simple moving average is $33.74 and its 200 day simple moving average is $38.41. The firm has a market capitalization of $1.69 billion, a PE ratio of 279.94 and a beta of 1.39. Vericel has a 1-year low of $29.24 and a 1-year high of $63.00.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $63.24 million for the quarter, compared to analyst estimates of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. Vericel’s revenue was up 20.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) EPS.

Hedge Funds Weigh In On Vericel

Large investors have recently added to or reduced their stakes in the business. Ameritas Advisory Services LLC purchased a new position in Vericel in the 2nd quarter worth $30,000. CWM LLC raised its position in Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 694 shares during the period. AlphaQuest LLC purchased a new position in Vericel in the 2nd quarter worth $60,000. Osaic Holdings Inc. raised its position in Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares during the period. Finally, GAMMA Investing LLC raised its position in Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 748 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.